- Home
- TAOP vs PCSA Comparison
TAOP vs PCSA Comparison
Compare TAOP & PCSA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TAOP
- PCSA
- Stock Information
- Founded
- TAOP 1993
- PCSA 2011
- Country
- TAOP China
- PCSA United States
- Employees
- TAOP N/A
- PCSA N/A
- Industry
- TAOP Computer Software: Prepackaged Software
- PCSA Biotechnology: Pharmaceutical Preparations
- Sector
- TAOP Technology
- PCSA Health Care
- Exchange
- TAOP Nasdaq
- PCSA Nasdaq
- Market Cap
- TAOP 3.1M
- PCSA 3.3M
- IPO Year
- TAOP N/A
- PCSA N/A
- Fundamental
- Price
- TAOP $3.02
- PCSA $0.17
- Analyst Decision
- TAOP
- PCSA Strong Buy
- Analyst Count
- TAOP 0
- PCSA 1
- Target Price
- TAOP N/A
- PCSA $1.00
- AVG Volume (30 Days)
- TAOP 25.3K
- PCSA 2.8M
- Earning Date
- TAOP 09-04-2025
- PCSA 10-29-2025
- Dividend Yield
- TAOP N/A
- PCSA N/A
- EPS Growth
- TAOP N/A
- PCSA N/A
- EPS
- TAOP N/A
- PCSA N/A
- Revenue
- TAOP $36,672,512.00
- PCSA N/A
- Revenue This Year
- TAOP N/A
- PCSA N/A
- Revenue Next Year
- TAOP N/A
- PCSA N/A
- P/E Ratio
- TAOP N/A
- PCSA N/A
- Revenue Growth
- TAOP N/A
- PCSA N/A
- 52 Week Low
- TAOP $2.82
- PCSA $0.15
- 52 Week High
- TAOP $29.40
- PCSA $1.50
- Technical
- Relative Strength Index (RSI)
- TAOP 37.22
- PCSA 31.24
- Support Level
- TAOP $3.04
- PCSA $0.18
- Resistance Level
- TAOP $3.99
- PCSA $0.23
- Average True Range (ATR)
- TAOP 0.32
- PCSA 0.02
- MACD
- TAOP 0.02
- PCSA -0.00
- Stochastic Oscillator
- TAOP 16.38
- PCSA 19.83
About TAOP Taoping Inc.
Taoping Inc is a provider of cloud-app technologies for smart city IoT platforms, digital advertising delivery, and other internet-based information distribution systems in China. Its operating segment includes Cloud-based Technology (CBT), Blockchain Technology (BT), and Traditional Information Technology (TIT). It generates maximum revenue from the CBT segment. CBT segment includes cloud-based products and services offered to customers in the private sector including new media, healthcare, education, and residential community management.
About PCSA Processa Pharmaceuticals Inc.
Processa Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on utilizing its regulatory science approach in the development of Next Generation Chemotherapy (NGC) oncology drug products. The company's strategic prioritization is to advance its pipeline of NGC proprietary small-molecule oncology drugs. The NGC products are new chemical entities, but the company works by changing the metabolism, distribution, and/or elimination of already FDA-approved cancer drugs or their active metabolites while maintaining the mechanism of how the drug kills cancer cells. The three NGC treatments in its pipeline are PCS6422 (also referred to as NGC-Cap), PCS3117, also referred to as NGC-Gemcitabine (NGC-Gem), and PCS11T, also referred to as NGC-Irinotecan (NGC-Iri).